Amal H Uzrail1 
,
Lubna Swellmeen2
For correspondence:- Amal Uzrail Email: auzrail@zu.edu.jo Tel:+6253821100
Accepted: 19 May 2020 Published: 30 June 2020
Citation: Uzrail AH, Swellmeen L. Leptin and systemic lupus erythematosus: A comprehensive review. Trop J Pharm Res 2020; 19(6):1329-1337 doi: 10.4314/tjpr.v19i6.30
© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Leptin, a cytokine-like hormone produced by adipocytes, modulates innate and adaptive responses of the immune system. Several reports have indicated that leptin exerts pro-inflammatory effects which significantly trigger autoimmune responses in chronic inflammatory diseases e.g. systemic lupus erythematosus (SLE), an inflammatory, multi-system disease characterized by the presence of auto-antibodies. Irrespective of contradictory results, many studies have indicated that leptin concentrations are increased in SLE patients. This might reflect genetic association, or a mechanism underlying the pathogenesis of SLE. To shed light on this possibility, recent studies investigated several polymorphism genes related to leptin in SLE patients from different ancestral groups. This review focuses on current understanding of the role of leptin in the pathogenesis of SLE and its immunomodulatory effects. This is expected to provide new leptin-based therapeutic interventions as modern approaches which are safer than the currently used ones for the treatment of SLE.
Archives
News Updates
Fulltext in PDF